Comparing the Efficacy and Safety of Linezolid versus Amoxicillin-Clavulanic Acid in the Management of Moderate to Severe Diabetic Foot Infections

Background :

Diabetic foot infections (DFIs) represent a major global health challenge, frequently leading to hospitalization, lower extremity amputation, and significant mortality. The choice of empirical antibiotic therapy is complicated by the polymicrobial nature of DFIs and the rising prevalence of multidrug-resistant organisms, particularly methicillin-resistant Staphylococcus aureus (MRSA).

This study aimed to compare the clinical and microbiological efficacy of Linezolid, a potent anti-Gram-positive agent, with Amoxicillin-Clavulanic Acid, a broad-spectrum antibiotic, in treating moderate to severe DFIs.

Methods :

In a prospective, open-label, randomized controlled trial conducted from 2021 to 2023, 300 patients with moderate to severe DFIs were enrolled. Participants were randomized to receive either Linezolid (600 mg IV/PO q12h) or Amoxicillin-Clavulanic Acid (1.2 g IV q8h or 625 mg PO q8h) for 7?14 days.

The primary outcome was clinical cure rate at the test-of-cure visit (14 days after treatment completion). Secondary outcomes included microbiological eradication, incidence of adverse events, and duration of hospital stay.

Results :

Linezolid demonstrated a significantly higher clinical cure rate compared to Amoxicillin-Clavulanic Acid (85.3% vs. 73.3%, p=0.01). Microbiological eradication was also superior in the Linezolid group (80.0% vs. 66.7%, p=0.02).

Subgroup analysis revealed Linezolid?s pronounced efficacy against MRSA (90% vs. 25%, p<0.001), whereas Amoxicillin-Clavulanic Acid was more effective against Gram-negative pathogens (82% vs. 48%, p=0.003).

The overall incidence of adverse events was comparable between groups (22% for Linezolid vs. 18% for Amoxicillin-Clavulanic Acid, p=0.40).

Conclusion :

Linezolid is a superior therapeutic option for DFIs where Gram-positive bacteria, especially MRSA, are suspected or confirmed. Amoxicillin-Clavulanic Acid remains a valuable agent for polymicrobial infections with significant Gram-negative involvement.

Tailoring empirical antibiotic therapy based on local antimicrobial resistance patterns and individual patient risk factors is crucial for optimizing outcomes in DFI management.